Premium
Radioisotopes reborn: radium‐223 and its role in the management of prostate cancer
Author(s) -
Parker Chris,
O'Sullivan Joe,
Heath Catherine
Publication year - 2015
Publication title -
trends in urology and men's health
Language(s) - English
Resource type - Journals
eISSN - 2044-3749
pISSN - 2044-3730
DOI - 10.1002/tre.486
Subject(s) - prostate cancer , radium 223 , radium , management of prostate cancer , medicine , cancer , clinical practice , oncology , medical physics , general surgery , family medicine , radiochemistry , chemistry , bone metastasis
This report is based on a seminar held during the 11th Annual Meeting of the British Uro‐oncology Group (BUG) in London, 12–13 September 2014. The seminar discussed the development of radium‐223 and its role in the management of prostate cancer, including an overview of the ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial and practical issues around the integration of radium‐223 into clinical practice.